Business Editors/Healthcare Editors
BIOWIRE2K
WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 10, 2006--Phase Forward
(NASDAQ: PFWD), a leading provider of data management solutions for
clinical trials and drug safety, today announced that GleneaglesCRC,
an Asian-based contract research organization (CRO), has selected
Phase Forward's Clintrial(TM) software for use in the CRO's Clinical
Data Management units in Singapore, the Philippines and China. The
Clintrial product is a regulatory-compliant clinical data management
system (CDMS) that provides a comprehensive and integrated environment
for the collection, management and cross-study analysis of paper-based
and electronically captured clinical and non-clinical data.
GleneaglesCRC provides clinical trial services to global and
regional pharmaceutical, biotechnology companies and research
institutes in Southeast Asian countries, offering experience with the
local culture and requirements, as well as access to a clinical
research network of more than 154 hospital sites located throughout
the region.
In addition to selecting the Clintrial software for use in its own
trials, GleneaglesCRC will be offering localized support for Phase
Forward's InForm(TM) electronic data capture (EDC) product.
GleneaglesCRC will provide support for Chinese-speaking and
Korean-speaking customers among a range of regional services.
"We believe that Phase Forward's products set the industry
benchmark for clinical trial software," said Lance Eminger, senior
business development manager in Singapore for GleneaglesCRC. "Data
generated by GleneaglesCRC can now be easily integrated with data from
the top pharmaceutical companies using the same Phase Forward
software. In addition, by establishing a single, consolidated audit
trail, Clintrial can help customers ensure that their trial management
and submission processes are compliant with regulations for new drug
applications (NDA)."
"GleneaglesCRC blends technology leadership, expertise in clinical
trials, cultural knowledge across the key markets of Asia and access
to an extensive network of trial sites," said Bob Weiler, president
and chief executive officer, Phase Forward. "As we respond to the
increased demand for our products and services on a global basis, we
are committed to working with leading CROs such as GleneaglesCRC to
provide our customers with local expertise."
GleneaglesCRC's Singapore office is the hub for conducting its
clinical data management. The data management unit in China is
tailored for local Chinese registration trials and the data management
unit in the Philippines will focus on high-volume, cost-effective data
entry projects for Phase IV trials required by the Philippines Bureau
of Food and Drugs (BFAD) regulatory authorities.
"We are pleased to be adopting Clintrial for conducting data
management and providing it as a quality service to our clients," said
Dr. Deng Ya Zhong, senior manager of biometrics in Singapore for
GleneaglesCRC. "Installing the data server in Singapore will also
allow remote access from our other data management units in China and
the Philippines. This will reinforce our commitment to data security
and reliability."
About GleneaglesCRC
GleneaglesCRC Pte Ltd is a wholly owned subsidiary of Parkway
Hospital Singapore Pte Ltd, one of Asia's premier, fully integrated
private healthcare providers with the largest network of private
hospitals and healthcare services in the region. GleneaglesCRC has a
clinical research network of more than 154 hospital sites located in
Singapore, Malaysia, Indonesia, Thailand, the Philippines, China, Hong
Kong, South Korea, India and Australia. For more information, visit
www.gleneaglescrc.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management
solutions for clinical trials and drug safety. The company offers
proven solutions for electronic data capture (InForm(TM)), clinical
data management (Clintrial(TM)), clinical trials signal detection
(CTSD(TM)), strategic pharmacovigilance (WebVDME(TM) and Signal
Management), adverse event reporting (Clintrace(TM)) and applied data
standards (WebSDM(TM)). In addition, the company provides services in
the areas of application implementation, hosting and validation, data
integration, business process optimization, safety data management and
industry standards. Phase Forward's products and services have been
utilized in over 10,000 clinical trials involving more than 1,000,000
clinical trial study participants at over 230 organizations and
regulatory agencies worldwide including: AstraZeneca, Boston
Scientific, Dana-Farber Cancer Institute, Eli Lilly, Food and Drug
Administration, GlaxoSmithKline, Merck, U.K. Medicines and Healthcare
Products Regulatory Agency, National Institutes of Health, Procter &
Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute,
Serono and Servier. Additional information about Phase Forward is
available at www.phaseforward.com.
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. This press release contains express or
implied forward-looking statements relating to, among other things,
the performance and features of Phase Forward's products and services,
demand for Phase Forward's products and services, future business and
operations plans of a Phase Forward customer, and the ability of Phase
Forward's customers to realize benefits from the use of Phase
Forward's products and services. These statements are neither promises
nor guarantees, but are subject to a variety of risks and
uncertainties, many of which are beyond Phase Forward's control, which
could cause actual results to differ materially from those
contemplated in these forward-looking statements. In particular, the
risks and uncertainties include, among other things, the ability of
Phase Forward's customers to realize benefits from the use of its
products and services, the possibility that customers' needs or plans
may change over time, and the possibility that the level of demand for
Phase Forward's products and services may vary. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. Phase Forward undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise. For
additional disclosure regarding these and other risks faced by Phase
Forward, see the disclosure contained in Phase Forward's public
filings with the Securities and Exchange Commission including, without
limitation, its most recent Quarterly Report on Form 10-Q.
CONTACT: Phase Forward
Gretchen Dock, 781-902-4413
gretchen.dock@phaseforward.com
or
CHEN PR, Inc.
Juli Greenwood, 781-672-3137
jgreenwood@chenpr.com
SOURCE: Phase Forward
